Tomoko Yoshioka

1.2k total citations
47 papers, 988 citations indexed

About

Tomoko Yoshioka is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Tomoko Yoshioka has authored 47 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 13 papers in Genetics and 13 papers in Oncology. Recurrent topics in Tomoko Yoshioka's work include Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Immune Cell Function and Interaction (5 papers). Tomoko Yoshioka is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Immune Cell Function and Interaction (5 papers). Tomoko Yoshioka collaborates with scholars based in Japan, United States and Russia. Tomoko Yoshioka's co-authors include Katsuya Okawa, Kazuma Aoki, Hiroaki Tabara, Naoto Takahashi, Takashi Kobayashi, Yoshihiro Kameoka, Akihiko Yoshimura, Masatomo Miura, Kenichi Sawada and Makoto Hirokawa and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and The EMBO Journal.

In The Last Decade

Tomoko Yoshioka

43 papers receiving 982 citations

Peers

Countries citing papers authored by Tomoko Yoshioka

Since Specialization

Citations

This map shows the geographic impact of Tomoko Yoshioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Yoshioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Yoshioka more than expected).

Fields of papers citing papers by Tomoko Yoshioka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Yoshioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Yoshioka. The network helps show where Tomoko Yoshioka may publish in the future.

Co-authorship network of co-authors of Tomoko Yoshioka

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Yoshioka. A scholar is included among the top collaborators of Tomoko Yoshioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Yoshioka. Tomoko Yoshioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy 2022 ·Cancer Chemotherapy and Pharmacology ·(unknown), Yumiko Akamine, (unknown), Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura	2
2	Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia 2022 ·Cancer Chemotherapy and Pharmacology ·(unknown), Takahiro Kobayashi, (unknown), (unknown), Akihiro Kitadate, Tomoko Yoshioka, Miho Nara, Yoshihiro Kameoka, Masatomo Miura, Naoto Takahashi	1
3	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy 2021 ·Scientific Reports ·(unknown), Naoto Takahashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura	5
4	Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib‐induced hypercholesterolaemia in patients with chronic myeloid leukaemia 2020 ·Journal of Clinical Pharmacy and Therapeutics ·(unknown), Yumiko Akamine, Shiori Sato, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura	4
5	The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration 2020 ·International Journal of Hematology ·(unknown), Masatomo Miura, Yuki Fujioka, (unknown), Takahiro Kobayashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi	9
6	Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis 2018 ·Medical Oncology ·Yuko Kanbayashi, Takeshi Ishikawa, Motohiro Kanazawa, Yuki Nakajima, (unknown), (unknown), Tomoko Yoshioka, (unknown), Toyoshi Hosokawa, Koichi Takayama, (unknown), Tetsuya Taguchi	3
7	Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis 2018 ·Medical Oncology ·Yuko Kanbayashi, Takeshi Ishikawa, Motohiro Kanazawa, Yuki Nakajima, (unknown), (unknown), Tomoko Yoshioka, Naohisa Yoshida, Toyoshi Hosokawa, Koichi Takayama, Tetsuya Taguchi	11
8	CDR3-independent expansion of Vδ1 T lymphocytes in acquired chronic pure red cell aplasia 2012 ·Immunology Letters ·(unknown), Makoto Hirokawa, Naohito Fujishima, Yukiko Abe, Masumi Fujishima, Yong‐Mei Guo, Kumi Ubukawa, Jiajia Liu, Tomoko Yoshioka, Yoshihiro Kameoka, H Saitoh, Hiroyuki Tagawa, Naoto Takahashi, Kenichi Sawada	5
9	Age-associated alteration of γδ T-cell repertoire and different profiles of activation-induced death of Vδ1 and Vδ2 T cells 2011 ·International Journal of Hematology ·(unknown), Makoto Hirokawa, Yong‐Mei Guo, Yukiko Abe, Jiajia Liu, Kumi Ubukawa, Naohito Fujishima, Masumi Fujishima, Tomoko Yoshioka, Yoshihiro Kameoka, (unknown), Hiroyuki Tagawa, Naoto Takahashi, Kenichi Sawada	39
10	Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient 2011 ·Clinica Chimica Acta ·Masatomo Miura, Naoto Takahashi, Syu‐ichi Kanno, (unknown), Miho Nara, (unknown), H Saitoh, Tomoko Yoshioka, Yoshihiro Kameoka, Naohito Fujishima, Hiroyuki Tagawa, Makoto Hirokawa, Kenichi Sawada	9
11	Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia 2010 ·Journal of Human Genetics ·Naoto Takahashi, Masatomo Miura, Stuart A. Scott, H.‐Matsuo Kagaya, Yoshihiro Kameoka, Hiroyuki Tagawa, H Saitoh, Naohito Fujishima, Tomoko Yoshioka, Makoto Hirokawa, Kenichi Sawada	131
12	TRAF6 Is Required for Generation of the B-1a B Cell Compartment as well as T Cell-Dependent and -Independent Humoral Immune Responses 2009 ·PLoS ONE ·Takashi Kobayashi, Tae Soo Kim, Anand Jacob, Matthew C. Walsh, Yuho Kadono, Ezequiel M. Fuentes‐Pananá, Tomoko Yoshioka, Akihiko Yoshimura, Masahiro Yamamoto, Tsuneyasu Kaisho, Shizuo Akira, John G. Monroe, Yongwon Choi	44
13	Mast cell leukemia with rapidly progressing portal hypertension 2009 ·Pathology International ·Masayuki Yoshida, Yuji Nishikawa, Yohei Yamamoto, Yuko Doi, Takuo Tokairin, Toshiaki Yoshioka, Yasufumi Omori, Atsushi Watanabe, Naoto Takahashi, Tomoko Yoshioka, Ikuo Miura, Kenichi Sawada, Katsuhiko Enomoto	5
14	TRAF6 and MEKK1 Play a Pivotal Role in the RIG-I-like Helicase Antiviral Pathway 2008 ·Journal of Biological Chemistry ·Ryoko Yoshida, Giichi Takaesu, Hideyuki Yoshida, (unknown), Tomoko Yoshioka, Yongwon Choi, Shizuo Akira, Taro Kawai, Akihiko Yoshimura, Takashi Kobayashi	88
15	Nuclear RanGAP Is Required for the Heterochromatin Assembly and Is Reciprocally Regulated by Histone H3 and Clr4 Histone Methyltransferase in Schizosaccharomyces pombe 2006 ·Molecular Biology of the Cell ·Hitoshi Nishijima, Jun‐ichi Nakayama, Tomoko Yoshioka, (unknown), Hideo Nishitani, Kei‐ichi Shibahara, Takeharu Nishimoto	16
16	Fluorescence In Situ Hybridization Monitoring of BCR-ABL-Positive Neutrophils in Chronic-Phase Chronic Myeloid Leukemia Patients during the Primary Stage of Imatinib Mesylate Therapy 2005 ·International Journal of Hematology ·Naoto Takahashi, Ikuo Miura, Yoshimi Kobayashi, Masaaki Kume, Tomoko Yoshioka, (unknown), (unknown), Kaoru Takahashi, (unknown), Yoshinari Kawabata, Makoto Hirokawa, (unknown), Ryo Ichinohasama, John F. DeCoteau, Akira Miura, Ken-ichi Sawada	8
17	Schizosaccharomyces pombe RanGAP Homolog, SpRna1, Is Required for Centromeric Silencing and Chromosome Segregation 2004 ·Molecular Biology of the Cell ·(unknown), Tomoko Yoshioka, Hitoshi Nishijima, Hideo Nishitani, Takeharu Nishimoto	12
18	Cytogenetic features of de novo CD5‐positive diffuse large B‐cell lymphoma: Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival 2004 ·Genes Chromosomes and Cancer ·Tomoko Yoshioka, Ikuo Miura, Masaaki Kume, Naoto Takahashi, Masataka Okamoto, Ryo Ichinohasama, Tadashi Yoshino, Motoko Yamaguchi, Makoto Hirokawa, Kenichi Sawada, Shigeo Nakamura	26
19	Conversion of Intravenously Administered .BETA.-Cryptoxanthin to a .BETA.-Carotene-Like Compound in Mouse Lung 2002 ·Journal of Nutritional Science and Vitaminology ·Yoshifumi Tomita, (unknown), Tomoko Yoshioka, Hoyoku Nishino, Masamichi Yano	2
20	Skin Reactions of Three Phenol Camphor Preparations 1980 ·The Journal of the Kyushu Dental Society ·(unknown), (unknown), Tomoko Yoshioka, Yuji Murakami, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact